Sankaranarayanan Kannan, M.Phil, PhD
Department of Leukemia, Division of Cancer Medicine
About Dr. Sankaranarayanan Kannan
Development of Novel Therapeutic Antibodies in AML
My pre-clinical research is focused on the development of novel targeted therapeutic antibodies such as chimeric antigen receptor T cells (CAR T cells) and antibody-drug conjugates (ADCs) in AML. Two AML-specific monoclonal antibodies (HSPA1L and CD200) are in the evolving stage. In fact, specificity of the HSPA1L based monoclonal antibody has already been confirmed in AML cell lines and primary patient samples. Further validation in AML samples in vitro is in progress. In addition, sequencing of heavy and light chain variable regions, synthesis of scFv and cloning into CAR cassette in lentiviral vector, production of CAR-encoded lentivirus, transduction of activated T cells with CAR-encoded lentivirus, T cell expansion, measurement and validation of CAR expression and assay for cytokine induction and cytotoxicity in preclinical AML models will be evaluated.
Pre-IND Studies in AML Models
Determining efficacy of Pre-Investigational New Drugs in AML models are established. Using pre-clinical leukemia models we can validate the efficacy of the new drugs. Pharmacodynamics and survival study based models are applied. For the reduced toxicity testing new drugs and its combination with chemotherapy or clinical therapeutic agents at low dose levels are performed in vitrousing primary AML samples and in vivopatient derived xenografts (PDXs) based validation models. Mainly, different AML subtypes and therapeutic resistant models are included.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
Research Interests
I have a broad interest in developing and validation of efficient therapeutic targets in pre-clinical models. In particular, the most fascinating area of targeted therapeutics is developing low-toxic effective therapeutic agents that benefits and improves quality of life of the patients. I want my research to be driven by pre-clinical efficacy studies that move to clinical trials.
Past and present research:
My research so far has focused on the molecular understanding of the receptor-ligand based oncogenic and anti-leukemic signaling in Notch receptor pathways. I have identified cell-type and context based anti-leukemic effects in AML using proteomics based assays. Further, Notch signaling mediated Polo-like kiase-1(PLK1), a cell cycle regulator, is down regulated in AML-specific manner. This provided an opportunity to use new investigational drugs, i.e., PLK1 inhibitors (Volasertib) and CYC140 in AML models. Currently, more pre-clinical inhibitors of PLK1 is in development by pharma companies.
In addition, my collaboration with Dr. Konopleva, professor in the department of Leukemia, we have identified novel therapeutic targets in AML-specific manner using proteomics and RNA- seq strategies. Currently we are generating monoclonal antibodies and progressing towards chimeric antigen receptor (CAR) T cell and antibody-drug conjugate(ADC) based immuno-therapeutic approaches for AML.
Future directions:
As we have established a AML-specific surface binding HSPA1L monoclonal antibody in leukemic cell lines we currently extended our studies using primary AML samples from patients. This work has the very appealing feature that it would be almost not binding to non-AML cells both in vitro and in vivo models, since the surface expression of HSPA1L is exclusive to AML not to normal bone marrow or peripheral blood monocytes(PBMCs). On a more pre-therapeutic level, I certainly feel that there are more effective therapeutic opportunities that awaits discoveries regarding HSPA1L existence on AML cells. In my current research I have established HSPA1L targeted anti-leukemic AML models and validating monoclonal antibody efficacies. I hope that I will achieve the right and effective and low-toxic therapeutic reagents for AML treatment in the coming years.
Education & Training
Degree-Granting Education
| 2002 | University of Madras, Madras, IN, Ph.D. in Glycoprotein–Gene regulation |
| 1995 | University of Madras, Madras, IN, M. Phil in Molecular Parasitology |
| 1994 | Madurai Kamaraj University, Madurai, IN, M.S. in Zoology |
| 1992 | Madurai Kamaraj University, Madurai, IN, BS in Zoology |
Experience & Service
Academic Appointments
Instructor, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center,, Houston, TX, 2021 - 2023
Instructor, Department of Pediatrics - Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2021
Research Scientist, Pediatric Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2013
Postdoctoral Research Associate, Vasculat-Gene Regulation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2007
Postdoctoral Research Associate, Cancer-Gene Regulation, Baylor College of Medicine, Houston, TX, 2002 - 2006
Research Associate, Council for Medical Research, The University of Madras, Madras, 2001 - 2002
Senior Research Fellow, Council for Medical Research, The University of Madras, Madras, 1999 - 2001
Research Fellow, Department of Biotechnology, Department of Biotechnology, Madras Veterinary College, Madras, 1995 - 1997
Honors & Awards
| 2017 - 2019 | My independent research in the identification of the oncogenic PLK1 kinase in B-ALL studies was awarded 2-year funding, Alex Lemonade Stand Foundation |
| 2016 | Oral presentation at the 29th annual meeting, American Society of Pediatrics Hematology/Oncology, Minneapolis, MN |
| 2016 | R21 grant received 15%ile Role: Principal Investigator, NCI special study section |
| 2001 | Extended Senior Research Fellow Award, Indian Council of Medical Research, New Delhi, India |
| 2001 | Frist Prize Award for PhD thesis, Society of Gastroenterology, Madras, India |
| 1999 | Senior Research Fellow Award, Indian Council of Medical Research, New Delhi, India |
| 1992 | Bachelor of Science with Distinction, Madurai Kamaraj University, Madurai, Tamilnadu, India |
Selected Publications
Peer-Reviewed Articles
- Kannan S, Li Y, Baran N, Yang X, Ghotbaldini S, Tatarata QZ, Yoshimura S, Li Z, Hsiao Y, Balachander SB, Andersen CL, Cidado J, Yu J, Jain N, Yang JJ, Konopleva MY. Anti-Leukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in Acute Lymphoblastic Leukemia Preclinical Models. Blood Adv 9(3):473-487, 2025. e-Pub 2025. PMID: 39561378.
- Wang Y, Tian X, Zhang W, Zhang Z, Lazcano R, Hingorani P, Roth ME, Gill JD, Harrison DJ, Xu Z, Jusu S, Kannan S, Wang J, Lazar AJ, Earley EJ, Erickson SW, Gelb T, Huxley P, Lahdenranta J, Mudd G, Kurmasheva RT, Houghton PJ, Smith MA, Kolb EA, Gorlick R. Comprehensive surfaceome profiling to identify and validate novel cell-surface targets in osteosarcoma. Mol Cancer Ther 21(6):903-913, 2022. e-Pub 2022. PMID: 35312779.
- Kannan, S, Irwin, ME, Herbrich, SM, Cheng, T, Patterson, LL, Aitken, MJ, Bhalla, K, You, MJ, Konopleva, M, Zweidler-McKay, PA, Chandra, J. Targeting the NRF2/HO-1 Antioxidant Pathway in FLT3-ITD-Positive AML Enhances Therapy Efficacy. Antioxidants 11(4), 2022. e-Pub 2022. PMID: 35453402.
- Kannan S, Aitken MJL, Herbrich SM, et al. Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. Mol Cancer Ther 18(9):1615–1627, 2019. e-Pub 2019.
- Herbrich SM, Kannan S, Nolo RM, Hornbaker M, Chandra J, Zweidler-McKay PA. Characterization of TRKA signaling in acute myeloid leukemia. Oncotarget 9(53):30092–30105, 2018. e-Pub 2018.
- Nolo R, Herbrich S, Rao A, Zweidler-McKay P, Kannan S, Gopalakrishnan V. Targeting P-selectin blocks neuroblastoma growth. Oncotarget 8(49):86657-86670, 2017. e-Pub 2017.
- Kannan S, Muthusamy VR, Whitehead KJ, Wang L, Gomes AV, Litwin SE, Kensler TW, Abel ED, Hoidal JR, Rajasekaran NS. Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy. Cardiovasc Res 100(1):63-73, 2013. e-Pub 2013. PMID: 23761402.
- Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, Nolo RM, Akers LJ, Hammitt RA, McMurray JS, Kornblau SM, Melnick A, Figueroa ME, Zweidler-McKay PA. Notch activation inhibits AML growth and survival: a potential therapeutic approach. Journal of Experimental Medicine 210(2):321-337, 2013. e-Pub 2013. PMID: 23359069.
- Miller CJ, Gounder SS, Kannan S, Goutam K, Muthusamy VR, Firpo MA, Symons JD, Paine R, Hoidal JR, Rajasekaran NS. Disruption of Nrf2/ARE signaling impairs antioxidant mechanisms and promotes cell degradation pathways in aged skeletal muscle. Biochim Biophys Acta 1822(6):1038-50, 2012. e-Pub 2012. PMID: 22366763.
- Levy AG, Zage PE, Akers LJ, Ghisoli ML, Chen Z, Fang W, Kannan S, Graham T, Zeng L, Franklin AR, Huang P, Zweidler-McKay PA. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Invest New Drugs 30(1):191-9, 2012. e-Pub 2012. PMID: 20890785.
- Muthusamy VR, Kannan S, Sadhaasivam K, Gounder SS, Davidson CJ, Boeheme C, Hoidal JR, Wang L, Rajasekaran NS. Acute exercise stress activates Nrf2/ARE signaling and promotes antioxidant mechanisms in the myocardium. Free Radic Biol Med 52(2):366-76, 2012. e-Pub 2012. PMID: 22051043.
- Gounder SS, Kannan S, Devadoss D, Miller CJ, Whitehead KS, Odelberg SJ, Firpo MA, Paine R, Hoidal JR, Abel ED, Rajasekaran NS. Impaired transcriptional activity of Nrf2 in age-related myocardial oxidative stress is reversible by moderate exercise training. PLoS One 7(9):e45697, 2012. e-Pub 2012. PMID: 23029187.
- Rajasekaran NS, Varadharaj S, Khanderao GD, Davidson CJ, Kannan S, Firpo MA, Zweier JL, Benjamin IJ. Sustained activation of nuclear erythroid 2-related factor 2/antioxidant response element signaling promotes reductive stress in the human mutant protein aggregation cardiomyopathy in mice. Antioxid Redox Signal 14(6):957-71, 2011. e-Pub 2011. PMID: 21126175.
- Kannan S, Fang W, Song G, Mullighan CG, Hammitt R, McMurray J, Zweidler-McKay PA. Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression. Blood 117(10):2891-900, 2011. e-Pub 2011. PMID: 21224467.
- Zweidler-McKay P, Graham C, Darwin J, Kannan S, Collins-Underwood R, Mullighan C. The Sun and the Sea: Balancing Ikaros in AML, T-ALL and B-ALL. Pediatric Blood & Cancer 56(6):923, 2011. e-Pub 2011.
- Zweidler-McKay P, Kannan S, Fang WD. NOTCH and PLK1: Targeting Novel Mechanisms in B-ALL. Pediatric Blood & Cancer 56(6):922, 2011. e-Pub 2011.
- Soorappan N, Varadharaj S, Khanderao GD, Davidson CJ, Kannan S, Firpo MA, Zweier J, Benjamin I. Antioxid Redox Signal. Sustained Activation of Nrf2/ARE Signaling Promotes Reductive Stress in the Human Mutant Protein Aggregation Cardiomyopathy in Mice Antioxid. Redox Signal 14(6):957-71, 2011. e-Pub 2011.
- Peyton KJ, Ensenat D, Azam MA, Keswani AN, Kannan S, Liu XM, Wang H, Tulis DA, Durante W. Arginase promotes neointima formation in rat injured carotid arteries. Arterioscler Thromb Vasc Biol 29(4):488-94, 2009. e-Pub 2009. PMID: 19164802.
- Kannan S, Jaiswal AK. Nrf3 negatively regulates antioxidant-response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. J Biol Chem 279:50810-17, 2004. e-Pub 2004.
- Kannan S, Lakku RA, Niranjali D, Jayakumar K, Steven AH, Taralakshmi VV, Chandramohan S, Balakrishnan R, Schmidt C, Halagowder D. Expression of peanut agglutinin-binding mucin-type glycoprotein in human esophageal squamous cell carcinoma as a marker. Mol Cancer 2:38, 2003. e-Pub 2003. PMID: 14613581.
- Reddi, AL, Kannan, S, Arulraj, HS, Devaraj, N, Devaraj, H. Serum α-N-acetylgalactosaminidase is associated with diagnosis/prognosis of patients with squamous cell carcinoma of the uterine cervix. Cancer Letters 158(1):61-64, 2000. e-Pub 2000. PMID: 10940510.
- Reddi AL, Kannan S, Arulraj HS, Niranjali S Devaraj H. Enzyme linked PNA lectin-binding assay of serum T-antigen in-patients with squamous cell carcinoma of the uterine cervix. Can Lett 1472:207-211, 2000. e-Pub 2000.
- Reddi AL, Kannan K, Arulraj HS, Niranjali S, DevarajH. Circulating levels of a-N-acetylgalactosaminidase in the sera of patients with squamous cell carcinoma of the uterine cervix. Can Lett 158:61-64, 2000. e-Pub 2000.
- Purushothaman V, Kannan S, Ravikumar MR, Ramasamy P. Development of in vitro primary cell culture from Penaeid shrimp, Penaeuis monodon, Penaeus indicus and a sand crab, Emeritas asiatica. Ind. J. Ani. Sci 68:1097-1099, 1998. e-Pub 1998.
Abstracts
- Kannan S, Sanaz G, wells J, Qi Z, Srividya B, Justin C, Marina K. Anti‐leukemic Activity of BCL‐2/BCL‐XL Dual Inhibitor ‐ AZD0466 in T‐Acute Lymphoblastic Leukemia preclinical models. Abstract nr 3075. Cancer Res 80((16 Suppl)), 2020. e-Pub 2020.
- Wang Y, Zhang Z, Kannan S, Zhang W, Roth M, Gill JB, Xu Z, Tian X, Wang J, Gorlick R. Surfaceome profiling in osteosarcoma: Identification of the candidate immunotherapeutic target: Abstract nr 2866. Cancer Res 79((13 Suppl)), 2019. e-Pub 2019.
- Kannan S, Livingston JA, Roth M, Benjamin J, Wang Y, Zhang Z, Zhang W, Wu C, Beird H, Futreal A, Gorlick R. Notch2 inhibition as a therapeutic intervention in osteosarcoma [abstract]. Cancer Res 79((13 Suppl)), 2019. e-Pub 2019.
- Wang Y, Kannan S, Zhang Z, Zhang W, Roth M, Gill JB, Xu Z, Tian X, Wang J, Gorlick R. Mapping the osteogenic lineage and identification of the cell of origin of osteosarcoma through high-dimensional analysis [abstract]. Cancer Res 79((13 Suppl)), 2019. e-Pub 2019.
- Herbrich S, Hornbaker M, Kannan S, Li G, Zweidler-McKay P. Targeting The Leukemia Niche: Pre-clinical Evaluation of Entrectinib, A Potent TRK Inhibitor, Aa A Novel Therapeutic Approach In Acute Myeloblastic Leukemia (AML). 4025 ASPHO's 29th Annual Meeting, 2016. e-Pub 2016.
- Kannan SN, Herbrich S, Zeng L, Zweidler-McKay P. NRF2 Inhibition Is A Novel Therapeutic Approach For AML via Enhancing Chemosensitivity. 4019 ASPHO, 2016. e-Pub 2016.
- Wiersma RE, Kannan S, Somanchi SS, Zeng L, Zweidler-McKay PA. A Novel DLL1-Anti-CD19 Chimeric Protein Effectively Targets Notch Activation to B-Cell Acute Lymphoblastic Leukemia and Induces Cell Death. Blood 126:4833, 2015. e-Pub 2015.
- Abu-Rmaileh N, Kannan S, Tsushima K, Whitehead K, Abel ED, Marrouche NF, Rajasekaran, NS. Atrial Remodeling and Fibrillation Precedes Ventricular Dysfunction in Human Mutant Protein Aggregation Cardiomyopathy. AHA-BCVS, 2013. e-Pub 2013.
- Abu-Rmaileh N, Kannan S, Tsushima K, Whitehead KS, Abel ES, Marrouche NF, Rajasekaran NS. Disruption og NRF2 Promotes Atrial Remodeling and Fibrillation on Aging. American Heart Association (AHA) and The Basic Cardiovascular Science (BCVS) Meetings in Las Vegas, NV, 2013. e-Pub 2013.
- Kannan S, Zweidler-McKay P. Notch/HES1 Signaling Stabilizes p53 Expression Via a Novel PARP1-Chfr-PLK1-Mediated Mechanism in B-ALL. 54th ASH Annual Meeting and Exposition in Atlanta, GA, 2012. e-Pub 2012.
- Kannan S, Zweidler-McKay PA. Notch/HES1 Signaling Stabilizes p53 Expression Via a Novel PARP1-Chfr-PLK10Mediated Mechanism in B-ALL. 54th Annual ASH Meeting and Exposition in Atlanta, GA, 2012. e-Pub 2012.
- Devadoss D, Sellamuthu S, Gounder SS, Kannan S, A-R N, Whitehead KS, Abel ED, Hoidal JR, Rajasekaran NS. Chronic Endurance Stress Induces Cardiac Remodeling in Aged Nrf2-null Mice. Society for Free Radical Biology and Medicine (SFRBM) in San Diego, CA, 2012. e-Pub 2012.
- Sellamuthu S, Gounder SS, Devadoss D, Kannan S, Abu-Ramelah N, Whitehead KS, Abel ED, Marrouche NF, Namakkai S, Rajasekaran NS. Disruption of Nrf2 Induces Atrial Rem,odeling and Fibrillation on Aging. Society for Free Radical Biology and Medicine (SFRBM) in San Diego, CA, 2012. e-Pub 2012.
- Zweidler-McKay P, Graham C, Darwin J, Kannan S, Collins-Underwood R, Mullighan C. The Sun and the Sea: Balancing Ikaros in AML, T-ALL and B-ALL. Pediatric Blood & Cancer 56(6):923-923, 2011. e-Pub 2011.
- Zweidler-McKay P, Kannan S, Fang WD. NOTCH and PLK1: Targeting Novel Mechanisms in B-ALL. Pediatric Blood & Cancer 56(6):922-922, 2011. e-Pub 2011.
- Levy AG, Akers LJ, Ghisoll ML, Graham TC, Zeng L, Nolo R, Zage PE, Fang W, Kannan S, Franklin AR, Huang P, Zweidler-McKay PA. Neuroblastoma and the Warburg Effect: The Novel Glycolysis Inhibitor 3-BrOP id Effective in Vitro and in Vivo. 22nd Annual Meeting of the American Society of Pediatric Hematology $ Oncology, 2009. e-Pub 2009.
- Kannan S, Zweidler-McKay PA. A Novel Cell-Specific Mechanism of Notch Signaling in Acute Lymphoblastic Leukemias - PARP1:HES1 Ratios. 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2009. e-Pub 2009.
- Ghisoli ML, Fang W, Levy AG, Graham TC, Nolo R, Kannan S, Pien C, Brown JL, Zweidler-McKay PA. Targeting TRKA: Preclinical Evaluation of AZ23 in Acute Myeloid Leukemia. Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2009. e-Pub 2009.
- Graham TC, Zeng L, Levy AG, Ghisoli ML, Kannan S, Nolo R, Fang W, Zage PE, Zweidler-McKay PA. TRKB In Neuroblastoma Following Pathways to Better Therapies. 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2009. e-Pub 2009.
- Kannan S, Zweidler-McKay PA. Cell Specific Consequences of Notch Signaling PARP1/HES1 Interaction Reveals a Novel Tumor Suppressor Mechanism. 51st Annual Meeting of the American Scociety of Hematology (#2388), 2009. e-Pub 2009.
- Akers LJ, Franklin AR, Fang W, Kannan S, Huang P, Zweidler-McKay PA. The novel glycolysis inhibitor, 3-BrOP, has broad activity against acute lymphoblastic leukemias (ALL) and synergizes with Rapamycin. 21st Annual Meeting of the American Society of Pediatric Hematology & Oncology, 2008. e-Pub 2008.
- Levy AG, Akers LJ, Zeng L, Nolo R, Zage PE, Fang W, Kannan S, Franklin AR, Huang P, Zweidler-McKay PA. The glycolysis inhibitor 3-BrOP synergizes with rapamycin and is a novel therapeutic combination for neuroblastoma. American Society of Pediatric Hematology & Oncology 21st Annual Meeting, 2008. e-Pub 2008.
- Ghisoli M, Fang W, Kannan S, Zweidler-McKay P, Levy A, Pien C, Omer C, Thress K, Brown J. TRK inhibition may be a novel therapeutic option for selected group of acute myeloblastic leukemias. 40th Congress of the international Society of Paediatric Oncology (SIOP) (#627), 2008. e-Pub 2008.
- Ghisoli ML, Fang W, Graham TC, Levy AG, Zeng L, Kannan S, Nolo RM, Pien C, Brown JL, Zweidler-McKay PA. Understanding the Role of TRKA Receptor in Acute Myeloid Leukemias: From Proliferation and Pro-Survival Signals to a Novel Therapeutic Approach. American Society of Hematology 50th Annual Meeting and Exposition (#3789), 2008. e-Pub 2008.
- Johnson FK, Johnson RA, Kannan S, Peyton KJ, William D. Endogenous Carbon Monoxide Production is Increased and Promotes Arteriolar Endothelial Sysfunction in Streptozotocin-Treated Diabetic Rats. Ameircan Diabetes Association's 66th Annual Scientific Sessions, 2006. e-Pub 2006.
- William D, Johnson FK, Johnson RA, Kannan S, Peyton KJ. Aarginase Induces Endothelial Dysgunction in Streptozotocin-Treated Diabetic Rats. American Diabetes Association's 66th Annual Scientific Sessions, 2006. e-Pub 2006.
- William D, Johnson FK, Peyton KJ, Kannan S, Johnson RA. Hyperhomocysteinemia Stimulates Endogenous Carbon Monoxide Production to Promote Endothelial Dysfunction in Rats. American Heart Association-Hypertension, 2006. e-Pub 2006.
- Kannan S, Jaiswal Anil K. Nrf3 Negatively Regulated ARE-Mediated Expression and Antioxidant Induction of Detoxifying Enzyme Genes. Society of Toxicology Annual Meeting, 2005. e-Pub 2005.
- Reddi AL, Kannan S, Arulraj HS, Niranjali S, Devaraj H. Quantitative determination of T-antigen in the sera of patients with SCC of the uterin cervix. XXVI Annual Conference and Symposium on Cancer Immunology in the New Millennium, 1999. e-Pub 1999.
Selected Presentations & Talks
National Presentations
- 2020. Surfaceome Profiling in Osteosarcoma: Identification of the Candidate Immunotherapeutic Target. Poster. 2020 Annual Meeting of American Association for Cancer Research. Philadelphia, PA, US.
- 2020. Anti-leukemic Activity of BCL-2/BCL-XL Dual Inhibitor - AZD0466 in T-Acute Lymphoblastic Leukemia Preclinical Models. Poster. 2020 Annual Meeting of the American Association for Cancer Research. Philadelphia, PA, US.
- 2020. Surfaceome Profiling in Osteosarcoma: Identification of the Candidate Immunotherapeutic Target. Poster. 2019 Annual Meeting of American Association for Cancer Research. Atlanta, GA, US.
- 2019. Notch2 Inhibition as a Therapeutic Intervention in Osteosarcoma. Poster. 2019 Annual Meeting of the Amercian Association for Cancer Research. Atlanta, GA, US.
- 2019. Mapping the Osteogeneic Lineage and Identification of the Cell of Origin of osteosarcoma Through High-Dimensional Analysis. Poster. 2019 Annual Meeting of the American Association for Cancer Research. Atlanta, GA, US.
- 2016. NRF2 Inhibition Is A Novel Therapeutic Approach for AML via Enhancing Chemosensitivity. Invited. 29th Annual Meeting of the American Society of Pediatric Hematology & Oncology. Minneapolis, MN, US.
- 2016. Targeting the Leukemia Niche: Pre-clinical Evaluation of Entrectinib, A Potent TRK Inhibitor as a Novel Therapeutic Approach in Acute Myeloblastic Leukemia (AML). Poster. 29th Annual Meeting of the American Society of Pediatric Hematology & Oncology. Minneapolis, MN, US.
- 2009. A Novel Cell-Specific Mechanism of Notch Signaling in Acute Lymphoblastic Leukemias - PARP1:HES1 Ratios. Poster. 22nd Annual Meeting of the American Society of Pediatric Hematology & Oncology. San Diego, CA, US.
Grant & Contract Support
| Date: | 2022 - 2024 |
| Title: | Defining the novel cancer testis antigen HSPA1L as immunotherapeutic target in AML |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1 R21 CA259324-01A1 |
| Date: | 2022 - 2024 |
| Title: | Pre-clinical Studies of anti-CLL-1, FLT3 and IL1RAP CAR-T Cells for Acute Myeloid Leukemia (AML) |
| Funding Source: | Precision Biosciences |
| Role: | Co-I |
| Date: | 2021 - 2023 |
| Title: | Characterization of CD70 expression and CD70 CAR T efficacy in vitro and in vivo with AML PDX models |
| Funding Source: | Allogene Therapeutics |
| Role: | Co-I |
| Date: | 2020 - 2021 |
| Title: | Dual Targeting of BCL-2/BCL-XL or BCL2-/MCL-1 in venetoclax-resistant AML |
| Funding Source: | AstraZeneca |
| Role: | Co-I |
| Date: | 2017 - 2019 |
| Title: | Targeting PLK1 as a Common Mechanism in Ph-like ALL |
| Funding Source: | Alex’s Lemonade Stand Foundation |
| Role: | Co-I |
| ID: | (ALSF ID# 4497 |
| Date: | 2015 - 2018 |
| Title: | Chronic Antioxidant Activation Induces Pre-leukemic Compensatory Response in MPN and MDS and Progress to Tumor Adaptive Reductive Stress in AML |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | PI |
| Date: | 2015 - 2018 |
| Title: | Modulating redox through antioxidant and exercise administration to prevent late effects seen in pediatric ALL survivors |
| Funding Source: | Leukemia & Lymphoma Society |
| Role: | PI |
| Date: | 2015 - 2019 |
| Title: | Defining and Treating Targetable Lesions in AYA Acute Lymphoblastic Leukemia |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP150006 |
| Date: | 2010 - 2015 |
| Title: | HES1 mediates cell-specific consequences of Notch signaling in ALL |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1R01CA138816-01A1 |
| Title: | Reductive Stress and Chemoresistance: A Novel Therapeutic Target in Human Acute Myeloblastic Leukemia (AML) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1 R21 CA208944-01 |
| Title: | Novel immunotherapy targets for pediatric and adult leukemia |
| Funding Source: | CPRIT |
| Role: | Collaborator |
Patient Reviews
CV information above last modified April 22, 2025